Keeping Your Pets Safe.

It’s not always easy to manage the array of dietary requirements, veterinary needs, and overall health of your furry, fluffy, or indeed scaly companions, so it’s of considerable concern when we see the FDA issuing corporate-wide warning letters to companies associated with contaminated pet food as it did last week.

With the sad stats that the contamination has caused hundreds of deaths and many more illnesses, Steven M. Solomon, M.P.H., D.V.M., director of the FDA’s Center for Veterinary Medicine stated that “It is imperative that manufacturers and distributors…understand their responsibility to comply with all requirements of federal law and FDA regulations and, when applicable, to implement a robust hazard analysis and risk-based preventive controls program. We’ll continue to hold companies accountable and protect animal health as a core element of the FDA’s public health mission.”

Thankfully the quick remedial action of voluntarily withdrawing the products by the supplier in question saved a much worse situation, but it doubtlessly confirms the need to take animal food and medicines much more seriously and step up the testing of active ingredients.

European-based QUINTA-ANALYTICA offers such testing and ​​pre-clinical evaluation of active ingredients for animal products, in addition to its Bioanalytical department cooperating with partners globally and conducting its own in-house toxicological and pharmacokinetic studies.

As holders of GMP certification for veterinary medicinal products, Quinta are regularly, and successfully, audited by the local State Institute for Drug Control (SÚKL) and the US FDA, making them the ideal pharma partner for companies wanting to stay on the right side of warning letters and offer nothing but the best for our dependable friends!

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.